GSK secures rights to Syndivia’s ADC asset for prostate cancer
GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal worth up to £268 million.…